Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

John Park

Citation

Annals of Oncology (2019) 30 (suppl_5): v1-v24. 10.1093/annonc/mdz238

Authors

J.J. Park1, A. Stewart1, M. Irvine1, B. Pedersen1, R. Kefford1, R. Diefenbach1, M.S. Carlino2, H. Rizos1

Author affiliations

  • 1 Department Of Biomedical Sciences, Macquarie University, 2109 - Sydney/AU
  • 2 Department Of Medical Oncology, The Crown Princess Mary Cancer Centre, 2145 - Westmead/AU
More

Resources

Abstract 2703

Background

Uveal melanoma (UM) is a rare cancer that arises from melanocytes in the uveal tract of the eye. Despite effective treatment for primary UM, > 50% of patients develop metastatic disease. There is currently no effective treatment for metastatic UM and median life expectancy is < 8 months. About 90% of UM are characterised by mutations in the GNAQ or GNA11 GTPases and several signalling cascades downstream of G-protein activation have been identified as potentially targetable. These include the protein kinase C (PKC), mitogen activated protein kinase (MAPK), phosphatidylinositol-3-kinases (PI3K), mammalian target of rapamycin (mTOR), and YES-associated protein (YAP) pathways. Aim to understand the relative contribution of oncogenic signaling pathways in proliferation and survival of UM.

Methods

The response 11 UM cell lines to 6 selective inhibitors was investigated using cell viability assays and cell cycle analyses by flow cytometry. Inhibition of selected pathways was examined using Western analysis of downstream effector proteins. The inhibitors used in this study included PKC inhibitors (AEB071 and LXS196), MEK inhibitor (trametinib), PI3K/mTOR inhibitor (BEZ235), YAP inhibitor (verteporfin) and ARF6 inhibitor (NAV2729).

Results

PKC inhibitors were most effective with 8 GNAQ/11 mutant UM cell lines showing some degree of sensitivity to each of the inhibitors, although sensitivity was usually associated with proliferative arrest rather than cell death. (see Table) Expression levels of pMARCKS and pERK were strongly inhibited by PKC inhibitors, however inhibition of these effector proteins did not reflect the degree of UM cell sensitivity.Table:

21P Summary of UM cell lines to each inhibitor. Combined result of cell viability assay and cell cycle analysis

Cell LineMutationTrametinibBEZ235NAV2729AEB071VerteporfinLXS196
Mel270GNAQsensitivesensitivesensitivesensitivesensitivesensitive
OMM1GNA11resistantsensitiveintermediate sensitivitysensitivesensitivesensitive
92.1GNAQresistantintermediate sensitivitysensitiveintermediate sensitivitysensitiveintermediate sensitivity
Mel202GNAQresistantintermediate sensitivitysensitiveintermediate sensitivitysensitiveintermediate sensitivity
OMM1.3GNAQresistantintermediate sensitivityresistantintermediate sensitivityresistantintermediate sensitivity
OMM1.5GNAQresistantresistantresistantintermediate sensitivityresistantintermediate sensitivity
MP41GNA11resistantresistantresistantintermediate sensitivityresistantintermediate sensitivity
MP46GNAQresistantresistantresistantresistantresistantintermediate sensitivity
MP38GNAQresistantresistantresistantresistantresistantresistant
Mel290Nilresistantintermediate sensitivityresistantresistantresistantresistant
Mel285Nilresistantresistantresistantresistantresistantresistant

Conclusions

The sensitivity of GNAQ/11 mutation UM cell lines to 6 targeted drugs is heterogeneous and no single dominant signalling pathway was identified. This suggest that multiple, independent signal pathways contribute to the survival of UM. Thus, inhibition of any single pathway is unlikely to be effective in the treatment of majority of metastatic UM.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings